facebook
twitter
search
search

Hormones may up breast cancer mortality

Oct. 19, 2010 at 11:54 PM

SAN ANTONIO, Oct. 19 (UPI) -- Combined hormone replacement therapy may not only increase the risk of breast cancer, it also doubles the risk of dying from it, U.S. researchers say.

In the original study, 16,608 postmenopausal women were randomized between placebo and a commonly used hormone combination of estrogen and progestin, with Dr. Schenken leading the San Antonio team, a major site for the study.

The initial results, published in 2003, showed taking combination therapy -- estrogen and progestin -- for a long period of time increased the risk of getting breast cancer by 25 percent. Most women stopped taking the combined hormone replacement therapy and some 17,000 fewer women per year got breast cancer, Schenken says.

The long-term follow-up of this initial study shows women who were taking combined hormone therapy not only had an increased risk of developing breast cancer, but developed deadlier forms of breast cancer -- doubling their risk of dying from breast cancer.

The findings are published in the Journal of the American Medical Association.

Related UPI Stories
Latest Headlines
Trending Stories
Device shown to 'smell' prostate cancer in men in trial
Scientists confirm second, more intense form of Lyme disease
Study: Sending fewer men to prison may slow spread of HIV
Einstein vindicated: Scientists find gravitational waves
Biden gathers forces to end cancer: Can he make a difference?